Investigation of the Pharmacokinetics, Safety, and Tolerability of Neladenoson Bialanate in Subjects With Hepatic Impairment (Classified as Child Pugh A and B) and in Age-, Weight-, and Gender-matched Healthy Subjects, Following a Single Oral Dose in a Single-center, Non-randomized, Non-controlled, Non-blinded Study
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Neladenoson bialanate (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Sponsors Bayer
Most Recent Events
- 30 Mar 2020 New trial record